论文部分内容阅读
目的了解经肝动脉化疗栓塞术(TACE)联合血管内皮抑素(Endostar)治疗兔VX2肝癌模型和临床原发性肝癌(HCC)患者后,肿瘤微血管密度(MVD)、血管内皮生长因子(VEGF)及CT灌注参数(BF、BV、PS)的变化情况。方法 60例兔VX2肝癌模型均分为三组,单纯TACE治疗组、联合治疗组(TACE联合Endostar)、对照组。40例经病理证实的HCC患者均分为两组,单纯TACE治疗组和联合治疗组(TACE联合Endostar)。分析各组实验动物或病例在治疗前后病理免疫组化(VEGF、MVD)和CT灌注扫描(BF、BV、PS)的改变。结果治疗前,三组兔VX2肝癌模型、两组HCC患者在BF、BV、PS和VEGF、MVD方面差异均无统计学意义。治疗后,联合治疗组(兔VX2肝癌模型、HCC患者)的VEGF、MVD均较单纯TACE组降低,BF、BV、PS均较单纯TACE组升高,差异均存在统计学意义。结论 TACE联合Endostar可以有效抑制兔VX2肝癌模型和临床HCCTACE术后的新生血管的形成,降低肿瘤复发或转移的几率,提高治疗效果。
Objective To investigate the relationship between tumor microvessel density (MVD), vascular endothelial growth factor (VEGF) and vascular endothelial growth factor (VEGF) in patients with VX2 hepatocellular carcinoma and clinical primary hepatocellular carcinoma (HCC) treated by TACE combined with endostar And CT perfusion parameters (BF, BV, PS) changes. Methods Sixty VX2 HCC models were divided into three groups: TACE alone group, TACE plus Endostar group, and control group. Forty patients with pathologically confirmed HCC were divided into two groups: TACE alone group and TACE plus Endostar group. The changes of pathological immunohistochemistry (VEGF, MVD) and CT perfusion scanning (BF, BV, PS) in experimental animals or cases before and after treatment were analyzed. Results Before treatment, there was no significant difference in BF, BV, PS, VEGF and MVD between the three groups of VX2 hepatocellular carcinoma and HCC patients. After treatment, the VEGF and MVD in the combined treatment group (rabbit VX2 hepatocellular carcinoma model and HCC patients) were lower than those in the pure TACE group. BF, BV and PS were higher than those in the pure TACE group, the differences were statistically significant. Conclusion TACE combined with Endostar can effectively inhibit the formation of neovascularization in VX2 liver cancer model and clinical HCCTACE in rabbits, reduce the chance of tumor recurrence or metastasis and improve the therapeutic effect.